Trends in cancer-targeted antibody-drug conjugates

Targeted Oncology

Volumn 9, Issue 1, 2014, Pages 1-8

  Bidard, François Clément ^a   Trédan, Olivier ^b  

^a INSTITUT CURIE   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Antibody drug conjugates; Cancer; Chemotherapy; Linker; Monoclonal antibodies

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CLATHRIN; DISULFIDE; GEMTUZUMAB OZOGAMICIN; HYDRAZONE DERIVATIVE; MONOCLONAL ANTIBODY; SULFIDE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTIBODY; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN ANTIBODY REACTION; BREAST CANCER; BYSTANDER EFFECT; CAVEOLA; CHEMICAL BOND; DRUG CONJUGATION; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; DRUG USE; HODGKIN DISEASE; HUMAN; INTRACELLULAR TRANSPORT; LARGE CELL LYMPHOMA; METASTASIS; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; TREND STUDY; ANIMAL; ANTIBODY SPECIFICITY; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; PROTEIN TRANSPORT; TRENDS;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BYSTANDER EFFECT; HUMANS; IMMUNOCONJUGATES; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN TRANSPORT;

EID: 84899498662     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0302-9     Document Type: Review

References (52)

1. Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6(5):349-356 (Pubitemid 46696550)
2. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23(9):1137-1146. doi:10.1038/nbt1141 (Pubitemid 41486395)
3. Ricart AD, Tolcher AW (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4(4):245-255. doi:10.1038/ncponc0774 (Pubitemid 46510534)
4. Carter P, Smith L, Ryan M (2004) Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11(4):659-687. doi:10.1677/erc.1.00766 (Pubitemid 40065544)
5. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66(4):2328-2337
6. Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H, Polakis P (2004) EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 64(3):781-788 (Pubitemid 38176871)
7. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14(3):154-169
8. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892. doi:10.1056/NEJMoa1113205
9. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426-4433
10. Lonberg N (2008) Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol 181:69-97. doi:10.1007/978-3-540-73259-4-4
11. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23(9):1105-1116. doi:10.1038/nbt1126
12. Becerril B, Poul MA, Marks JD (1999) Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun 255(2):386-393. doi:10.1006/bbrc.1999.0177 (Pubitemid 29292269)
13. Maeda H, Fang J, Inutsuka T, Kitamoto Y (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3(3):319-328. doi:10.1016/S1567-5769(02)00271- 0 (Pubitemid 36293960)
14. Lee CM, Tannock IF (2010) The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 10:255. doi:10.1186/1471-2407-10-255
15. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D (2000) A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 6(2):78-81 (Pubitemid 30469166)
16. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 17(2):478-484 (Pubitemid 29075231)
17. Salzberg AA, Dedon PC (2000) DNA bending is a determinant of calicheamicin target recognition. Biochemistry 39(25):7605-7612 (Pubitemid 30422080)
18. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5):1807-1814 (Pubitemid 38268977)
19. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17(1):114-124 (Pubitemid 43157592)
20. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778-784 (Pubitemid 36791396)
21. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(16):2698-2704. doi:10.1200/JCO.2009.26.2071
22. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol Off J Am Soc Clin Oncol 29(4):398-405. doi:10.1200/JCO.2010.29.5865
23. Elias DJ, Hirschowitz L, Kline LE, Kroener JF, Dillman RO, Walker LE, Robb JA, Timms RM (1990) Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 50(13):4154-4159 (Pubitemid 20225644)
24. Kaneko T, Willner D, Monkovic I, Knipe JO, Braslawsky GR, Greenfield RS, Vyas DM (1991) New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity. Bioconjug Chem 2(3):133-141
25. Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Cheng X, Okada M, Oishi T, Terakawa N (1998) Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82(4):697-702
26. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law CL, Wahl AF (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281(15):10540-10547 (Pubitemid 43864594)
27. Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ (2006) Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther 5(6):1474-1482 (Pubitemid 44070484)
28. Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255(2):232-240 (Pubitemid 47268641)
29. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5(2):147-159. doi:10.1038/nrd1957
30. Razani B, Woodman SE, Lisanti MP (2002) Caveolae: from cell biology to animal physiology. Pharmacol Rev 54(3):431-467
31. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH (2004) Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18(2):316-325 (Pubitemid 38240048)
32. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID (2005) Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105(3):1295-1302. doi:10.1182/blood-2004-07-2784 (Pubitemid 40170906)
33. Mukherjee S, Ghosh RN, Maxfield FR (1997) Endocytosis. Physiol Rev 77(3):759-803 (Pubitemid 27328740)
34. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15(12):5268-5282. doi:10.1091/mbc.E04-07-0591 (Pubitemid 39564723)
35. Weisz OA (2003) Acidification and protein traffic. Int Rev Cytol 226:259-319
36. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blattler WA, Goldmacher VS (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66(6):3214-3221
37. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res Off J Am Assoc Cancer Res 16(3):888-897. doi:10.1158/1078-0432.CCR-09-2069
38. Sievers EL, Linenberger M (2001) Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 13(6):522-527 (Pubitemid 33027906)
39. FDA (2010) Mylotarg (gemtuzumab ozogamicin): market withdrawal. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm216458.htm?utm-campaign= Google2&utm-source=fdaSearch&utm-medium=website&utm-term= ucm216458&utm-content=1. Accessed 9 Nov 2013
40. FDA (2011) FDA Approval for brentuximab vedotin. http://www.cancer.gov/ cancertopics/druginfo/fda-brentuximabvedotin. Accessed 9 Nov 2013
41. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812-1821. doi:10.1056/NEJMoa1002965
42. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 18(1):248-255. doi:10.1158/1078-0432.CCR-11-1425
43. Katz J, Janik JE, Younes A (2011) Brentuximab vedotin (SGN-35). Clin Cancer Res Off J Am Assoc Cancer Res 17(20):6428-6436. doi:10.1158/1078-0432. CCR-11-0488
44. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 30(18):2183-2189. doi:10.1200/JCO.2011.38.0410
45. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 30(18):2190- 2196. doi:10.1200/JCO.2011.38.0402
46. Burris HA 3rd, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD (2011) Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer 11(5):275-282. doi:10.1016/j.clbc.2011.03.018
47. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290. doi:10.1158/0008-5472.CAN-08-1776
48. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69(5):1229-1240. doi:10.1007/s00280-011-1817-3
49. Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52(5):691-703. doi:10.1177/0091270011403742
50. Gupta M, Wang B, Carrothers TJ, Joshi A, LoRusso PM, Chu W, Shih T, Loecke D, Girish S (2011) Exposure-response analysis in patients with HER2-positive (HER2+) metastatic breast cancer (MBC) to assess the effect of T-DM1 on QTc prolongation. Paper presented at the ASCPT Conference, Dallas, TX, 3 April 2011
51. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Lu M, Burington B, Agresta S, Rugo H (2010) A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients with HER2-positivemetastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. Paper presented at the European Society for Medical Oncology (ESMO), Milan, 8-12 October 2010
52. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783-1791. doi:10.1056/NEJMoa1209124